Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Trophos Launches First Study of Olesoxime in Multiple Sclerosis Patients

Published: Tuesday, March 19, 2013
Last Updated: Tuesday, March 19, 2013
Bookmark and Share
A Phase 1b study in RRMS patients is starting in three MS reference centers in France.

Trophos SA has announced the initiation of a phase 1b study of olesoxime in multiple sclerosis (MS) patients as a complementary therapy to their treatment with interferon beta.

The clinical trial is designed to demonstrate the safety and tolerability of olesoxime as a co-medication with immunomodulatory treatments, interferon beta being the most frequent first line therapy for relapsing remitting MS.

The study will also be a pilot study to assess the feasibility of various magnetic resonance imaging (MRI) procedures to detect signs of neuroprotection and/or myelin repair in a multicenter trial.

The clinical trial is in preparation for future large-scale clinical trials to assess efficacy of olesoxime to prevent progressive disability in MS patients.

The trial, led by professor Jean Pelletier (AP-HM/CNRS-CRMBM/CEMEREM), will be conducted in three leading MS clinical centers in France, located in Marseille (AP-HM CHU Timone), Rennes (CHU de Rennes) and Reims (CHU de Reims).

Two MRI specialist labs (UMR CNRS 7339-CRMBM/CEMEREM in Marseille and INRIA VISAGES in Rennes) will analyze the imaging biomarker data acquired in the study.

This trial is the objective of an ANR-funded project, Translate MS-Repair, awarded to Trophos and this consortium (see press release October 11, 2012).

"MS is a chronic inflammatory disease leading to demyelination and axonal degeneration in the central nervous system. Today there are a number of effective treatments to control these relapsing inflammatory episodes in MS; however, they have little effect on progressive disability in MS patients," said Dr. Rebecca Pruss, Trophos' chief scientific officer.

Dr. Pruss continued, "It is also now recognized that MS is a chronic neurodegenerative disease. It affects 2.5 million people globally and is the first cause of non-traumatic disability in young adults. As a result, there is a very high unmet need for agents to promote myelin repair and prevent the neurodegeneration that underlies progressive disability in MS."

"This study is expected to provide further evidence of the safety and tolerability of olesoxime as a complementary therapy to immunomodulatory treatments used by the majority of MS patients," said Dr. Pascal Longlade, Trophos' chief medical officer.

Dr. Longlade continued, "We see this study as the first step in the development of olesoxime to prevent disability in both relapsing remitting as well as progressive forms of MS."

"MS disease progression has a market potential of over USD 1 billion. Trophos hopes that gathering leading experts in MS and bringing our consortium based approach to MS will make a real difference to this so far unmet medical need," said Christine Placet, CEO, Trophos. "Trophos remains committed to bringing solutions to conditions like MS and SMA, as well as cardiac reperfusion injury."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Trophos Announces Top-Line Results in Pivotal Trial of Olesoxime in SMA
Promising results for the maintenance of motor function in spinal muscular atrophy - a rare, serious and debilitating pediatric-onset neurodegenerative disease.
Thursday, March 20, 2014
Trophos Completes Pivotal Phase II/III Study of Olesoxime in SMA
The French patients’ association AFM-Telethon supported the study which evaluates the ability of olesoxime to preserve the neuromuscular function of SMA patients.
Friday, November 08, 2013
Trophos Announces Final Patient Completion of Phase II Study of TRO40303
The study, a critical part of the EU funded MitoCare Project, will evaluate the reduction of reperfusion injury by TRO40303 in acute ST-elevation myocardial infarction (STEMI) patients.
Thursday, October 03, 2013
Trophos Announces Positive Interim Review in Pivotal Study of Olesoxime in SMA
Topline results expected in the fourth quarter of 2013.
Monday, March 04, 2013
Trophos Appoints JSB Partners as Global Partnership Advisor
Life science advisor to advise Trophos on strategic partnerships for orphan disease and niche indication candidates.
Monday, December 31, 2012
Trophos Program Boosted by EUR 1 Million Grant for Olesoxime in Progressive MS
Agence Nationale de la Recherche awards second grant to Trophos led consortium for Phase Ib/IIa clinical study.
Friday, October 12, 2012
Marceline Clementine Appointed Chief Financial Officer
Ms. Clementine is now responsible for all administrative and financial services at Trophos.
Wednesday, September 19, 2012
Trophos Announces Conclusion of MitoTarget Consortium
EU funded 3-year project spearheaded by orphan disease specialist Trophos reports results from neurodegenerative program to the European Commission.
Wednesday, August 01, 2012
Trophos Appoints Christine Placet as Chief Executive Officer
Christine becomes CEO under a succession plan designed to provide continuity for Trophos.
Thursday, June 14, 2012
Trophos Announces Results of Phase III Study of Olesoxime in ALS
Company continues its ongoing programs and financed until at least the end of 2013.
Wednesday, December 14, 2011
Trophos Initiates Phase II Study for Novel Cardioprotective Compound, TRO40303, in Acute MI
European study being performed as part of Trophos-led, EU funded MitoCare project.
Tuesday, November 01, 2011
Trophos Completes Patient Enrolment in Pivotal Efficacy Study of Olesoxime in SMA
Topline results expected in second half of 2013.
Friday, September 09, 2011
Trophos Successfully Completes Phase 1 Study for Novel Cardioprotective Compound, TRO40303
Phase 2 proof-of-concept study in acute myocardial infarction planned for second half 2011 with MitoCare EU consortium.
Friday, February 25, 2011
Trophos to Lead new MitoCare Consortium Awarded EUR 6 Million to Study Cardioprotective Compound, TRO40303
Program of translational research to study innovative approaches to reducing cardiac ischemia-reperfusion injury.
Wednesday, December 15, 2010
Trophos Initiates Pivotal Efficacy Study of Olesoxime in Spinal Muscular Atrophy
European study supported by partnership with the Association Française contre les Myopathies.
Monday, October 18, 2010
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!